Proteomics labs worldwide can now access SomaLogic’s industry-leading 7,000-plex SomaScan® Assay with the Certified Site program

Rhea-AI Summary

SomaLogic, a leader in proteomics technology, has launched its global SomaLogic™ Certified Site program, enabling institutions to run the 7,000-plex SomaScan® Assay in their labs. This program allows certified labs to conduct research and generate revenue as service providers. The SomaScan Assay measures over 7,000 proteins per sample and provides various assay kits for different sample types. Certified sites, including those at the NIH and Washington University, receive extensive support, training, and equipment servicing. New sites are expected to be added in 2023 across multiple regions.

Positive

• Launch of the SomaLogic Certified Site program expands global access to the SomaScan Assay.
• Over 7,000 protein measurements available per sample enhance research capabilities.
• Institutions can generate revenue by providing assay services.

Negative

• None.

BOULDER, Colo., Dec. 07, 2022 (GLOBE NEWSWIRE) --  SomaLogic, Inc., a leader in proteomics technology, announced today the full-scale global launch of the SomaLogic™ Certified Site program, which will allow institutions around the world to run the 7,000-plex SomaScan^® Assay in their own labs. By becoming a SomaLogic Certified Site, labs can run assays on SomaLogic’s SomaScan^® Platform—the largest commercially available proteomics platform—and accelerate their own research and generate revenue as a service provider. SomaLogic Certified Sites receive support services, on-site training and equipment servicing.

“The Certified Sites program allows us to expand the availability of our platform to labs and institutions around the world,” said Executive Vice President of SomaLogic’s Life Sciences business, Adam Taich. “We are pleased with the success of our current certified sites and are confident in making our powerful proteomic platform available globally.”

The SomaLogic Certified Site program gives labs and institutions—including academia and contract research organizations (CROs)—access to the SomaScan Assay, with 7,288 protein measurements per sample and up to 90 samples per assay kit. To support researchers working in many different areas, SomaLogic offers dedicated assay kits for many sample types, including human EDTA plasma, human serum, human urine, cell lysate and human cerebral spinal fluid. SOMAmer^® reagents have been optimized for specificity with specific binding to target epitopes with coefficients of variation (CVs) of approximately 5 percent, versus polyclonal antibodies that can result in non-specific binding, with CVs as high as 25 percent.

SomaLogic launched the Certified Site program with labs at the National Institutes of Health, Washington University and Beth Israel Deaconess Medical Center. In November, Molecular Genomics in Singapore became the first site in Asia to offer the 7,000-plex SomaScan^® Assay and provide SomaScan data to their customers. New sites are expected to be added in 2023 in Asia Pacific, EMEA and North America.

SomaLogic’s proprietary SomaScan Platform was designed to be a universal platform that can be applied across research and discovery, translational research and biopharmaceutical development, and clinical applications. SomaLogic can run approximately 7,000 protein measurements on a single 55 microliter plasma or serum sample. The company has run more than 550,000 samples to date.

About SomaLogic 
SomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s personalized measurement of important changes in an individual’s proteins over time. For more information, visit www.somalogic.com and follow @somalogic on Twitter.  

Forward Looking Statements Disclaimer
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements, other than statements of historical fact included in this press release, regarding our strategy, future operations, financial position, estimated revenues, projections, prospects, plans and objectives of management are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “forecast,” “guidance,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “continue,” “will likely result,” “possible,” “potential,” “predict,” “pursue,” “target” and similar expressions, although not all forward-looking statements contain such identifying words. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements do not guarantee future performance and involve known and unknown risks, uncertainties and other factors.   Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including factors which are beyond SomaLogic’s control. You should carefully consider these risks and uncertainties, including, but not limited to, those factors described under Part I, Item 1A – “Risk Factors” in our Annual Report on Form 10-K and other filings we make with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SomaLogic assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company will not and does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Media Contact  
Emilia Costales  
720-798-5054  
ecostales@somalogic.com   

Investor Contacts 
Marissa Bych 
Gilmartin Group LLC 
Marissa@gilmartinir.com

FAQ

What is the SomaLogic Certified Site program and its significance for SLGC?

The SomaLogic Certified Site program allows labs worldwide to run the 7,000-plex SomaScan® Assay, enhancing research capabilities and generating revenue.

How many proteins can be measured using the SomaScan Assay and what is its capacity?

The SomaScan Assay measures over 7,000 proteins and can analyze up to 90 samples per assay kit.

What support do certified sites receive under the SomaLogic program?

Certified sites receive training, equipment servicing, and ongoing support from SomaLogic.

Which institutions have joined the SomaLogic Certified Site program?

Institutions like the National Institutes of Health and Washington University are among the first certified sites.